HMG-CoA reductase inhibitors (statins) as anticancer drugs (review)

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• HMG-CoA reductase inhibitors (statins) possess anticancer properties beyond lipid reduction.
• Statins affect cellular processes crucial for cancer metastasis, including angiogenesis and cell motility.
• The prenylation of GTPases like Ras and Rho is vital for cell signaling and is inhibited by statins.

Purpose of the Study:

• To review current data supporting the use of statins in cancer therapy.
• To discuss the mechanisms by which statins may inhibit tumor progression and metastasis.
• To evaluate the feasibility of incorporating statins into existing cancer treatment protocols.

Main Methods:

• Review of existing scientific literature on statins and cancer.
• Analysis of molecular mechanisms underlying statin's effects on cancer cells.
• Discussion of clinical implications and potential therapeutic applications.

Main Results:

• Statins inhibit key metastatic processes: gene expression, angiogenesis, cell adhesion, motility, and invasiveness.
• Statins modulate apoptotic cell death and cellular sensitivity to anticancer treatments.
• Inhibition of Ras/Rho GTPase prenylation by statins disrupts critical signaling pathways.

Conclusions:

• Statins demonstrate significant potential as an adjunct therapy in cancer treatment.
• The molecular mechanisms involve interference with GTPase prenylation and downstream signaling.
• Given extensive clinical use, statins could be rapidly integrated into oncological regimens.